Gencor’s new glucose-support ingredient Trigogen is derived from fenugreek: Natural Products Expo West report

A new ingredient from Gencor (Irvine, CA) called Trigogen is designed to support metabolic health and glucose levels. The company launched the ingredient during March’s Natural Products Expo West trade show in Anaheim, CA.

Trigogen is a novel, standardized fenugreek seed extract focused on the plant alkaloid compound trigonelline. It is shown to support fasting and postprandial glucose levels.

According to a Gencor press release, “Trigogen’s promising benefits have been shown in a preclinical and a recently published human clinical trial. Gencor’s laboratory study examined how trigonelline may work to support metabolic health and demonstrated an insulin-sensitizing effect. The study revealed that ß-cells (cells within the pancreas responsible for insulin production) attenuated endoplasmic reticulum (ER) stress, which may help support ß-cell health and function. The research also revealed improvement in the antioxidant status of the pancreas.”

In addition, a recently published double-blind, randomized, placebo-controlled human clinical trial demonstrated a significant improvement in fasting blood glucose, 2-hour postprandial glucose response, and triglycerides in subjects who supplemented with Trigogen.¹ The 12-week study was performed on 48 adults with “some degree of impaired glucose metabolism.” Subjects took either placebo or 250 mg twice daily of Trigogen.

The results indicate that Trigogen supports healthy blood sugar levels in a fasted state and also supports a healthy blood sugar response to a meal.

In a press release, Ramasamy Venkatesh, cofounder of Gencor and business development specialist, stated, “What makes our product unique is its ability to support healthy pre- and postprandial glucose levels.”

Reference

1. Pickering, E.; Steels, E.; Rao, A.; Steadman, K.J. An Exploratory Study of the Safety and Efficacy of a Trigonella foenum-graecum Seed Extract in Early Glucose Dysregulation: A Double-Blind Randomized Placebo-Controlled Trial. Pharmaceutics. 2022, 14 (11): 2453. DOI: 10.3390/pharmaceutics14112453